logo-loader
viewRedx Pharma PLC

Redx Pharma's chief scientific officer talks grant funding for its fibrosis project

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project.

They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the discovery of new treatments and will focus on potential new drugs for idiopathic pulmonary fibrosis (IPF), a life-threatening fibrotic lung condition.

Quick facts: Redx Pharma PLC

Price: 14.25 GBX

AIM:REDX
Market: AIM
Market Cap: £27.08 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 rallies as Italians ban short selling

Headlines from the Proactive UK newsroom. The FTSE 100 rallied this morning even though Asian markets suffered more pain overnight.  London’s blue chip index opened around 157 points higher at 5,395 after giving up 639 points yesterday. Italy has introduced a temporary ban on...

2 weeks, 3 days ago

2 min read